类风湿关节炎中Janus激酶抑制剂与生物改善病情抗风湿药相关活动性结核发生风险的比较
这项韩国全国性匹配队列研究纳入16760例新发类风湿关节炎患者(3352例JAK抑制剂使用者与13408例bDMARD使用者),比较活动性结核风险。JAK抑制剂使用者结核风险显著低于bDMARD使用者(HR 0.37,95%CI 0.22-0.62);但潜伏结核感染患者无论接受何种治疗风险相当,预防治疗依从性低者风险显著升高(HR 2.78,95%CI 1.74-4.44)。
要点
- JAK抑制剂使用者活动性结核风险显著低于bDMARD使用者(HR 0.37,95%CI 0.22-0.62)。
- 潜伏结核感染患者中,预防治疗依从性低者结核风险显著高于无潜伏感染者(HR 2.78,95%CI 1.74-4.44)。
- 有潜伏结核感染的类风湿关节炎患者无论接受JAK抑制剂还是bDMARD,结核风险相当。
核心结论
- 在韩国,使用JAK抑制剂的类风湿关节炎患者活动性结核风险显著低于bDMARD使用者。
- 但有潜伏结核感染的患者无论接受JAK抑制剂还是bDMARD,风险相当。
- 作者认为,尤其在结核预防治疗依从性低的患者中,警惕性结核监测至关重要。
研究设计与样本
- 全国性匹配队列研究,回顾性识别2012年至2021年韩国国民健康保险服务数据库中新发类风湿关节炎并接受bDMARD或JAK抑制剂、且近期行潜伏结核感染筛查的成人患者。
- 随访至2022年底观察活动性结核发生,在倾向评分匹配队列中使用Cox比例风险回归估计HR。
- 匹配后共16760例类风湿关节炎患者,其中JAK抑制剂使用者3352例、bDMARD使用者13408例。
主要发现
- 16760例匹配患者中18.8%因潜伏结核感染接受了结核预防治疗。
- 总体而言,JAK抑制剂使用者结核风险显著低于bDMARD使用者(HR 0.37,95%CI 0.22-0.62)。
- 在接受潜伏结核感染治疗的患者中,治疗依从性低者结核风险显著高于无潜伏结核感染者(HR 2.78,95%CI 1.74-4.44)。
- 无潜伏结核感染且使用JAK抑制剂的患者在所有年龄和性别中结核风险均显著低于bDMARD使用者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This study aimed to evaluate the risk of tuberculosis associated with the use of Janus kinase (JAK) inhibitors or biological disease-modifying antirheumatic drugs (bDMARDs) in patients diagnosed with rheumatoid arthritis (RA) in South Korea. METHODS: In this nationwide matched-cohort study, we retrospectively identified adult patients with new-onset RA from the National Health Insurance Service database who were prescribed bDMARDs or JAK inhibitors and recently underwent latent tuberculosis infection (LTBI) screening during 2012‒2021, and followed them up until the end of 2022 for the development of active tuberculosis. HRs were estimated using Cox proportional hazards regression in a propensity score-matched cohort. RESULTS: Among 16 760 matched patients with RA (3352 JAK inhibitor users and 13 408 bDMARD users), 18.8% received tuberculosis preventive therapy for LTBI. Overall, JAK inhibitor users had a significantly lower risk of tuberculosis than bDMARD users (HR (95% CI)=0.37 (0.22 to 0.62)). Among the patients treated for LTBI, patients with low treatment adherence had a significantly higher risk than those without LTBI (HR (95% CI)=2.78 (1.74 to 4.44)). Patients without LTBI and using JAK inhibitors had a significantly lower risk of tuberculosis across all ages and sexes compared with bDMARD users. CONCLUSION: Patients with RA using JAK inhibitors have a significantly lower risk of active tuberculosis than bDMARD users in South Korea; however, patients with RA having LTBI are equally at risk regardless of the treatment received (JAK inhibitor vs bDMARD). Therefore, vigilant tuberculosis monitoring, especially in patients with low adherence to tuberculosis preventive therapy, is essential.
引用
- Song YK, Lee J, Jo J, et al. Comparison of active tuberculosis occurrence associated with Janus kinase inhibitors and biological DMARDs in rheumatoid arthritis. RMD Open. 2024. PMID: 38609319. doi:10.1136/rmdopen-2023-003946
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。